134 related articles for article (PubMed ID: 25472626)
1. Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature.
Aigner B; Bauernhofer T; Petru E; Niederkorn A; Arzberger EJ; Richtig E
Dermatology; 2014; 229(4):288-92. PubMed ID: 25472626
[TBL] [Abstract][Full Text] [Related]
2. A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane.
Bos AM; van der Graaf WT; Willemse PH
Acta Oncol; 2001; 40(4):541-2. PubMed ID: 11504316
[No Abstract] [Full Text] [Related]
3. Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane.
Uges JW; Vollaard AM; Wilms EB; Brouwer RE
Int J Clin Oncol; 2006 Dec; 11(6):467-70. PubMed ID: 17180516
[TBL] [Abstract][Full Text] [Related]
4. Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines.
Jensen JN; Lock-Andersen J; Langer SW; Mejer J
Scand J Plast Reconstr Surg Hand Surg; 2003; 37(3):174-5. PubMed ID: 12841619
[TBL] [Abstract][Full Text] [Related]
5. Dexrazoxane: new indication. Anthracycline extravasation: continue using dimethyl sulfoxide.
Prescrire Int; 2009 Feb; 18(99):6-8. PubMed ID: 19382398
[TBL] [Abstract][Full Text] [Related]
6. Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation.
Arroyo PA; Perez RU; Feijoo MA; Hernandez MA
J Cancer Res Ther; 2010; 6(4):573-4. PubMed ID: 21358106
[TBL] [Abstract][Full Text] [Related]
7. Recall phenomenon following epirubicin.
Wilson J; Carder P; Gooi J; Nishikawa H
Clin Oncol (R Coll Radiol); 1999; 11(6):424-5. PubMed ID: 10663338
[TBL] [Abstract][Full Text] [Related]
8. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
9. Recovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatment.
Vos FY; Lesterhuis WJ; Brüggemann RJ; Graaf WT
Anticancer Drugs; 2012 Jan; 23(1):139-40. PubMed ID: 21934601
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
11. Treatment of anthracycline extravasation with dexrazoxane -- clinical experience.
Frost A; Gmehling D; Azemar M; Unger C; Mross K
Onkologie; 2006 Jul; 29(7):314-8. PubMed ID: 16874015
[TBL] [Abstract][Full Text] [Related]
12. Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation.
Tyson AM; Gay WE
Ann Pharmacother; 2010 May; 44(5):922-5. PubMed ID: 20371757
[TBL] [Abstract][Full Text] [Related]
13. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
14. Treatment of anthracycline extravasation with dexrazoxane.
Langer SW; Sehested M; Jensen PB
Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
[TBL] [Abstract][Full Text] [Related]
15. Massive breast necrosis after extravasation of a full anthracycline cycle.
Vasconcelos I; Schoenegg W
BMJ Case Rep; 2013 Oct; 2013():. PubMed ID: 24142568
[TBL] [Abstract][Full Text] [Related]
16. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.
Andersen KG; Jensen MB; Kehlet H; Gärtner R; Eckhoff L; Kroman N
Acta Oncol; 2012 Nov; 51(8):1036-44. PubMed ID: 22676048
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo study on the antioxidant activity of dexrazoxane.
Galetta F; Franzoni F; Cervetti G; Regoli F; Fallahi P; Tocchini L; Carpi A; Antonelli A; Petrini M; Santoro G
Biomed Pharmacother; 2010 Apr; 64(4):259-63. PubMed ID: 19932589
[TBL] [Abstract][Full Text] [Related]
18. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
[TBL] [Abstract][Full Text] [Related]
20. A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer.
Pacchiarotti I; Mazzarini L; Pellegrini P; Venturelli V; Sani G; Sánchez-Moreno J; Mancinelli I; Tatarelli R; Kotzalidis GD; Girardi P
Gen Hosp Psychiatry; 2007; 29(5):461-3. PubMed ID: 17888816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
